Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Connect Biopharma Holdings Ltd

Healthcare US CNTB

2.12USD
0.03(1.44%)

Last update at 2026-06-24T20:00:00Z

Day Range

2.042.18
LowHigh

52 Week Range

0.693.82
LowHigh

Fundamentals

  • Previous Close 2.09
  • Market Cap151.48M
  • Volume311667
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-57.37000M
  • Revenue TTM0.06M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.06M
  • Diluted EPS TTM-1.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -55.28300M -15.40500M -61.98600M -795.01800M -1305.12700M
Minority interest - - - - -
Net income -55.48000M -15.62800M -62.10600M -797.05500M -1306.82400M
Selling general administrative 20.34M 19.23M 16.05M 139.44M 122.44M
Selling and marketing expenses - - 13.51M - -
Gross profit 0.06M 26.03M -0.98800M - -
Reconciled depreciation 0.70M 0.66M 0.99M 6.94M 4.08M
Ebit -58.07400M -22.45200M -69.05600M -805.58900M -631.43600M
Ebitda -57.37000M -21.79200M -68.33600M -762.06900M -1305.08300M
Depreciation and amortization 0.70M 0.66M 0.72M 43.52M -673.64700M
Non operating income net other - - - - -
Operating income -58.07400M -22.45200M -69.05600M -805.58900M -631.43600M
Other operating expenses 58.14M 48.48M 69.06M 785.22M 621.47M
Interest expense - - 0.02M 0.14M 0.04M
Tax provision 0.20M 0.22M 0.12M 2.04M 1.70M
Interest income 2.27M 4.45M 2.71M 10.71M 0.62M
Net interest income 2.27M 4.45M 2.69M 10.57M 0.58M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.20M 0.22M 0.12M 2.04M 1.70M
Total revenue 0.06M 26.03M 0.00000M 0.00000M 0.00000M
Total operating expenses 58.14M 48.48M 69.06M 785.22M 621.47M
Cost of revenue - 0.66M 0.99M - -
Total other income expense net 2.79M 7.05M 7.07M 10.57M -673.69100M
Discontinued operations - - - - -
Net income from continuing ops -55.48000M -15.62800M -59.50300M -797.05500M -1306.82400M
Net income applicable to common shares - - - - -1306.82400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 56.08M 101.28M 125.89M 1211.93M 1855.66M
Intangible assets 0.04M 0.05M 0.06M 22.04M 22.55M
Earning assets - - - - -
Other current assets 6.43M 2.20M - - 3.95M
Total liab 14.10M 9.12M 24.85M 115.06M 119.83M
Total stockholder equity 41.98M 92.17M 101.04M -3175.22000M 1735.83M
Deferred long term liab - - - - -
Other current liab 11.16M 7.80M 3.00M 24.39M 32.84M
Common stock 0.01000M 0.01000M 0.01000M 0.07M 0.07M
Capital stock 0.01000M 0.01000M 0.01000M 0.07M 0.07M
Retained earnings -400.83500M -345.35500M -539.34700M -3175.22000M -2378.16500M
Other liab - - - - 5.00M
Good will - - - - -21.98700M
Other assets - - - - 18.81M
Cash 38.34M 78.23M 106.01M 550.27M 1706.88M
Cash and equivalents - - - - -
Total current liabilities 13.61M 8.46M 24.26M 108.82M 114.67M
Current deferred revenue 0.17M 0.16M 13.32M - -
Net debt -37.65500M -78.05400M -105.54200M -547.27600M -1706.08700M
Short term debt 0.32M 0.15M 0.28M 1.29M 0.63M
Short long term debt - - - - -
Short long term debt total 0.69M 0.18M 0.47M 3.00M 0.79M
Other stockholder equity 444.00M 439.18M 648.26M -71.18600M 4155.17M
Property plant equipment - - - - 82.16M
Total current assets 50.93M 96.96M 120.97M 1084.94M 1754.13M
Long term investments - - 0.00000M 65.74M -
Net tangible assets - - - - 1735.27M
Short term investments 6.00M 15.48M 12.65M 511.25M 0.00000M
Net receivables 0.16M 1.05M 0.18M 1.61M 47.26M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.96M 0.34M 7.66M 83.14M 81.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.19100M -1.66600M -7.87800M 71.12M -41.24400M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.65M 0.03M 0.13M 0.24M 18.81M
Deferred long term asset charges - - - - -
Non current assets total 5.15M 4.32M 4.92M 126.99M 101.52M
Capital lease obligations 0.69M 0.18M 0.47M 3.00M 0.79M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 10.25M -3.45100M 75.16M -571.31000M 13.50M
Change to liabilities - - - - 56.60M
Total cashflows from investing activities 9.82M -3.45100M 75.16M - -34.02500M
Net borrowings - - -0.29000M - -0.80500M
Total cash from financing activities 1.09M 0.23M -0.24600M -0.62500M 1316.10M
Change to operating activities - - - - -19.66500M
Net income -55.48000M -15.62800M -59.38300M -795.01800M -1305.12700M
Change in cash -39.88700M -27.43100M 27.00M -1156.60600M 696.80M
Begin period cash flow 78.23M 105.66M 79.01M 1706.88M 1010.08M
End period cash flow 38.34M 78.23M 106.01M 550.27M 1706.88M
Total cash from operating activities -51.20600M -23.61200M -47.93000M -679.66500M -544.92600M
Issuance of capital stock - - 0.04M 0.13M 1431.78M
Depreciation 0.70M 0.66M 0.99M 6.94M 4.08M
Other cashflows from investing activities 0.78M 0.12M -0.08400M - -22.28400M
Dividends paid - - - - 0.24M
Change to inventory - - - - -
Change to account receivables 0.78M -0.78900M 1.04M - -16.11600M
Sale purchase of stock - - 0.00000M 0.00000M -3.67400M
Other cashflows from financing activities 1.09M 0.23M 75.16M 0.76M -110.95400M
Change to netincome - - - - 737.00M
Capital expenditures 0.43M 0.75M 0.29M 29.32M 47.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.58M -15.49000M 9.48M 49.02M 20.82M
Stock based compensation 3.73M 6.73M 3.26M 45.60M 57.86M
Other non cash items -0.73600M 0.12M -2.27900M -9.24800M 0.04M
Free cash flow -51.64000M -24.36200M -48.22400M -708.98500M -592.45500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CNTB
Connect Biopharma Holdings Ltd		 0.03 1.44% 2.12 - 0.77 2366.83 3.61 1684.77 0.19
NVO
Novo Nordisk A/S		 -0.01 0.02% 47.41 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 6.78 1.45% 475.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.40 0.87% 623.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Connect Biopharma Holdings Ltd

3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Wubin Pan M.B.A., Ph.D. Co-Founder, Pres & Chairman of Directors 1965
Dr. Zheng Wei Ph.D. Co-Founder, CEO & Director 1964
Mr. Steven Chan Chief Financial Officer 1972
Mr. Jiang Bian J.D. Gen. Counsel & Chief Compliance Officer NA
Dr. Lei Sun Ph.D. VP of Biologics & Head of CMC 1964
Dr. Raul Collazo Ph.D. VP & Global Head of Medical Affairs NA
Dr. Malinda V. Longphre Ph.D. Head of US Clinical Operations NA
Dr. Chin Lee M.D., M.P.H. Chief Medical Officer 1970
Dr. Wubin Pan M.B.A., Ph.D. Co-Founder, President & Chairman of the Board of Directors 1965
Mr. Jiang Bian J.D. General Counsel & Chief Compliance Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.